Related Experiment Videos
In vitro activity of polyoxin D and nikkomycin Z against Encephalitozoon cuniculi
Ingo Sobottka1, Katrin Bartscht, Peter Schäfer
1Institute of Medical Microbiology and Immunology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. sobottka@uke.uni-hamburg.de
Abstract:
Microsporidia of the genus Encephalitozoon are emerging protozoal agents that mainly infect immunocompromised patients with AIDS. At present, disseminated infections with members of the genus Encephalitozoon can only be successfully treated with albendazole. As chitin is a basic component of the microsporidian spore. we evaluated, in vitro, the susceptibility of a human-derived strain of Encephalitozoon cuniculi to polyoxin D and nikkomycin Z, which are known competitive inhibitors of chitin synthetase enzymes. Using an in vitro assay, polyoxin D at 1, 10 and 100 microg/ml significantly reduced the number of parasitic foci on days 6, 9, and 15 post-infection. However, nikkomycin Z revealed a marked but lower reduction in the number of parasitic foci than polyoxin D. A significant reduction of parasitic foci was achieved for nikkomycin Z at 10 and 100 microg/ml up to day 9 post-infection. Polyoxin D was approximately tenfold more effective in our in vitro assay than nikkomycin Z.
Insights
Polyoxin D effectively inhibited Encephalitozoon cuniculi growth in vitro by targeting chitin synthesis. This finding suggests potential new treatments for microsporidian infections in immunocompromised patients.
Area of Science:
- * Infectious Diseases
- * Parasitology
- * Drug Discovery
Background:
- * Microsporidia, particularly Encephalitozoon species, are opportunistic pathogens causing severe infections in immunocompromised individuals, notably those with AIDS.
- * Current treatments for disseminated Encephalitozoon infections rely on albendazole, highlighting the need for alternative therapeutic strategies.
- * Chitin, a key component of microsporidian spores, presents a potential target for novel antifungal agents.
Purpose of the Study:
- * To investigate the in vitro efficacy of polyoxin D and nikkomycin Z, known chitin synthetase inhibitors, against a human-derived strain of Encephalitozoon cuniculi.
- * To compare the inhibitory effects of polyoxin D and nikkomycin Z on the proliferation of Encephalitozoon cuniculi.
- * To assess the potential of targeting chitin synthesis as a therapeutic approach for microsporidiosis.
Main Methods:
- * An in vitro susceptibility assay was employed to evaluate the effects of polyoxin D and nikkomycin Z on Encephalitozoon cuniculi.
- * Parasitic foci were quantified at various time points (days 6, 9, and 15 post-infection) following treatment with different concentrations of the inhibitors.
- * The efficacy of the two chitin synthesis inhibitors was directly compared based on their ability to reduce parasitic foci.
Main Results:
- * Polyoxin D demonstrated significant reduction in parasitic foci at concentrations of 1, 10, and 100 microg/ml on days 6, 9, and 15 post-infection.
- * Nikkomycin Z also reduced parasitic foci significantly at 10 and 100 microg/ml up to day 9 post-infection, but its effect was less pronounced than that of polyoxin D.
- * In vitro, polyoxin D was approximately tenfold more effective than nikkomycin Z in inhibiting Encephalitozoon cuniculi growth.
Conclusions:
- * Polyoxin D exhibits potent in vitro activity against Encephalitozoon cuniculi, suggesting its potential as a therapeutic agent for microsporidiosis.
- * Targeting chitin synthesis pathways with inhibitors like polyoxin D offers a promising avenue for developing new treatments against emerging microsporidian infections.
- * Further research is warranted to explore the clinical applicability and in vivo efficacy of polyoxin D for treating human microsporidiosis.